Botaky Biotechnology: Net profit in 2025 is expected to decrease by 70.94% year-on-year, with a proposed dividend of 7 yuan per share.

Botuo Biology disclosed its annual report on April 24, reporting that in 2025, the company achieved operating income of 448 million yuan, a decrease of 19.91% compared to the same period last year; net profit attributable to shareholders was 49.2534 million yuan, a decrease of 70.94% compared to the same period last year; and basic earnings per share were 0.34 yuan. The company plans to distribute a cash dividend of 7 yuan for every 10 shares. During the reporting period, in the first half of 2025, market volatility was triggered by the US government imposing tariffs multiple times, leading to a decline in the company's exports to the US. Additionally, domestic sales of respiratory tract testing products and mosquito-borne products in Latin America, such as dengue fever, decreased year-on-year due to intensified industry competition and cyclical fluctuations in the infectious disease testing market.